Volume grows, but policy cuts and price mix threaten margins
- In Q1 2026, Diagnostic Information Services made up 97.8% of net revenue.
- Management expects PAMA cuts to hit 2027 revenues by roughly 1%.
- Total revenue per requisition fell 4.2% in Q3 2026 due to the business mix.
- A new Apple Health app integration lets users order over 50 biomarkers directly.
- An October 2026 cyber incident targeted a non-EMR system without material disruption.
Bigger contracts, persistent policy risks
Quest is a scale story in medical testing. Doctors, hospitals, employers, and consumers send samples to Quest. Quest runs the tests, reports the results, and gets paid by health plans, government programs, hospitals, employers, or patients.
The bull case improved because a court vacated the FDA rule for Laboratory Developed Tests, or LDTs. These are tests built and used inside a lab. That matters because Quest wants Advanced Diagnostics, such as cancer and genetics tests, to grow faster and carry better margins. Consumer testing is also gaining momentum with a new Apple Health app integration that allows direct biomarker ordering.
The operating story is mixed. The new Corewell Health relationship and testing for Fresenius Medical Care dialysis clinics continue to drive volume. However, these large hospital and dialysis contracts bring lower revenue per requisition. In Q3 2026, revenue per requisition decreased 4.2% versus the prior year period, primarily driven by this business mix.
The bear case remains tied to policy and IT vulnerability. Management quantified upcoming PAMA reimbursement cuts at roughly 1% of 2027 revenues, a drag of over $120 million, and is lobbying heavily for the RESULTS Act as a fix. OBBBA could also reduce consolidated revenue by 50 to 60 basis points by 2028. An October 2026 cyber incident highlighted the ongoing IT risks.
Paid per test, helped by scale
Quest makes most of its money by performing lab tests. A requisition is the order that travels with a patient sample and tells Quest which tests to run and who should be billed. Revenue depends on how many requisitions Quest gets and how much it earns per requisition.
The main business is Diagnostic Information Services. In Q1 2026, it was 97.8% of net revenue. The smaller Diagnostic Solutions group was 2.2% and includes risk assessment services for insurers and healthcare technology businesses.
Scale is the key advantage. More volume can help Quest spread lab, logistics, technology, and billing costs over more tests. The Invigorate program is meant to deliver 3% annual cost savings and productivity gains, using automation and artificial intelligence in areas such as patient services, logistics, lab work, revenue services, IT, and procurement.
The model breaks when price, mix, or execution moves the wrong way. Government fee schedules, payer pressure, and big lower-priced contracts can hurt revenue per requisition. IT outages, like the October 2026 cyber incident, or a messy Project Nova rollout could also slow the business.
Routine tests fund harder tests
Routine clinical testing
This is the core testing work ordered by doctors and hospitals. It supplies the volume that makes Quest's network valuable.
Hospital lab services
Quest is winning more work from hospitals that need lower costs and help with lab staffing. Corewell Health and Fresenius are the key contracts driving volume.
Advanced Diagnostics
This includes brain health, women's health, genetic, molecular, oncology, and cardiometabolic tests. The LDT court ruling lowered the near-term rule risk for this higher-value area.
Haystack MRD
Haystack MRD is aimed at finding minimal residual disease, which can signal cancer recurrence. It recently won New York State approval.
questhealth.com
This is Quest's consumer-initiated testing platform. A new integration lets users order tests directly via the Apple Health app for over 50 biomarkers.
Employer services
This includes drug testing and population health services. It stabilized after a period of headwinds and is now contributing to revenue growth.
One main engine
The segment mix is from Quest's Q1 2026 Form 10-Q. Quest reports revenue mainly as Diagnostic Information Services and Diagnostic Solutions, while also managing customer channels such as physicians, hospitals, consumers, and employers.
What can go wrong
PAMA reimbursement cuts
High impact · Medium oddsPAMA affects what Medicare pays for many lab tests. Management estimates PAMA cuts will impact 2027 revenues by roughly 1%, or over $120 million. The company is pushing for the RESULTS Act to fix the data collection process before 2027.
Low-price volume mix
Medium impact · High oddsLarge contracts can add a lot of volume but may carry lower revenue per requisition. In Q3 2026, revenue per requisition fell 4.2% due to the Corewell and Fresenius business mix. Quest needs scale benefits to offset that margin pressure.
IT and cybersecurity risks
Medium impact · Medium oddsQuest depends on technology for orders, logistics, and billing. In October 2026, the company disclosed unauthorized access to a test ordering system used by non-EMR clients. The company is also running a multi-year IT modernization effort called Project Nova.
OBBBA revenue drag
Medium impact · High oddsQuest says OBBBA and the planned expiration of enhanced premium tax credits could reduce consolidated revenue by up to 50 to 60 basis points by 2028 compared with 2025. The hit is tied mainly to ACA Exchange Plan revenue.
Acquisition and venture integration
Medium impact · Medium oddsQuest is integrating recent deals and partnerships, including LifeLabs, Spectra, and Corewell Health. Delays or cost overruns could reduce the benefit of the deals.
Future LDT legislation
Medium impact · Low oddsA court vacated the FDA's LDT rule, and the FDA did not appeal. That removed the immediate threat. Congress could still try to pass a new law for LDT oversight, which would bring back uncertainty for Advanced Diagnostics.
In one breath
What does Quest Diagnostics do?
Quest runs lab tests on patient samples and sends results back to doctors, hospitals, patients, and other healthcare customers. Its main business is Diagnostic Information Services.
Why does the LDT ruling matter for Quest?
LDTs are tests developed and used inside a lab. A court vacated the FDA's LDT rule in March 2025, which reduced near-term regulatory risk for Quest's Advanced Diagnostics business.
Is Quest Diagnostics mainly a growth stock?
Quest has growth drivers, such as hospital partnerships and advanced tests, but it is also a mature healthcare services company. Finn's view is balanced because policy risk, pricing pressure, and valuation still matter.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- October 25, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Quest Diagnostics Incorporated in Finn's Diagnostics & Research industry ranking.

